Trial of IFN or STI571 before proceeding to allografting for CML?
Ten-year survival of IFN-treated low risk CML patients is about 40%, and more in cytogenetic responders. Allografting has a cure rate of up to 75%, but is associated with considerable procedure related morbidity and mortality. One out of three or four is likely not to survive. A comparative quantifi...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
31 August 2000
|
| In: |
Leukemia
Year: 2000, Jahrgang: 14, Heft: 9, Pages: 1560-1562 |
| ISSN: | 1476-5551 |
| DOI: | 10.1038/sj.leu.2401874 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/sj.leu.2401874 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/2401874 
|
| Verfasserangaben: | R. Hehlmann |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1802593225 | ||
| 003 | DE-627 | ||
| 005 | 20220820185135.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220519s2000 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/sj.leu.2401874 |2 doi | |
| 035 | |a (DE-627)1802593225 | ||
| 035 | |a (DE-599)KXP1802593225 | ||
| 035 | |a (OCoLC)1341460213 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hehlmann, Rüdiger |d 1941- |e VerfasserIn |0 (DE-588)1037003489 |0 (DE-627)751737879 |0 (DE-576)390939463 |4 aut | |
| 245 | 1 | 0 | |a Trial of IFN or STI571 before proceeding to allografting for CML? |c R. Hehlmann |
| 264 | 1 | |c 31 August 2000 | |
| 300 | |a 3 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 19.05.2022 | ||
| 520 | |a Ten-year survival of IFN-treated low risk CML patients is about 40%, and more in cytogenetic responders. Allografting has a cure rate of up to 75%, but is associated with considerable procedure related morbidity and mortality. One out of three or four is likely not to survive. A comparative quantification of survival after BMT and IFN treatment suggests that a trial of IFN (and possibly STI 571) before proceeding to allografting is a viable, and in low risk patients a probably preferable option. | ||
| 650 | 4 | |a Cancer Research | |
| 650 | 4 | |a general | |
| 650 | 4 | |a Hematology | |
| 650 | 4 | |a Intensive / Critical Care Medicine | |
| 650 | 4 | |a Internal Medicine | |
| 650 | 4 | |a Medicine/Public Health | |
| 650 | 4 | |a Oncology | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia |d London : Springer Nature, 1997 |g 14(2000), 9, Seite 1560-1562 |h Online-Ressource |w (DE-627)32046699X |w (DE-600)2008023-2 |w (DE-576)094139733 |x 1476-5551 |7 nnas |a Trial of IFN or STI571 before proceeding to allografting for CML? |
| 773 | 1 | 8 | |g volume:14 |g year:2000 |g number:9 |g pages:1560-1562 |g extent:3 |a Trial of IFN or STI571 before proceeding to allografting for CML? |
| 856 | 4 | 0 | |u https://doi.org/10.1038/sj.leu.2401874 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/2401874 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220519 | ||
| 993 | |a Article | ||
| 994 | |a 2000 | ||
| 998 | |g 1037003489 |a Hehlmann, Rüdiger |m 1037003489:Hehlmann, Rüdiger |d 60000 |d 61200 |e 60000PH1037003489 |e 61200PH1037003489 |k 0/60000/ |k 1/60000/61200/ |p 1 |x j |y j | ||
| 999 | |a KXP-PPN1802593225 |e 4136169167 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["32046699X"],"issn":["1476-5551"],"zdb":["2008023-2"]},"title":[{"title":"Leukemia","subtitle":"normal and malignant hemopoiesis ; a peer-reviewed journal","title_sort":"Leukemia"}],"origin":[{"publisherPlace":"London ; Basingstoke [u.a.] ; Basingstoke","dateIssuedKey":"1997","dateIssuedDisp":"1997-","publisher":"Springer Nature ; Stockton Press ; Nature Publ. Group"}],"recId":"32046699X","disp":"Trial of IFN or STI571 before proceeding to allografting for CML?Leukemia","type":{"media":"Online-Ressource","bibl":"periodical"},"part":{"year":"2000","volume":"14","text":"14(2000), 9, Seite 1560-1562","pages":"1560-1562","extent":"3","issue":"9"},"language":["eng"],"pubHistory":["Nachgewiesen 11.1997 -"],"note":["Gesehen am 15.03.04"]}],"origin":[{"dateIssuedKey":"2000","dateIssuedDisp":"31 August 2000"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title":"Trial of IFN or STI571 before proceeding to allografting for CML?","title_sort":"Trial of IFN or STI571 before proceeding to allografting for CML?"}],"physDesc":[{"extent":"3 S."}],"id":{"eki":["1802593225"],"doi":["10.1038/sj.leu.2401874"]},"person":[{"display":"Hehlmann, Rüdiger","given":"Rüdiger","role":"aut","family":"Hehlmann"}],"recId":"1802593225","note":["Gesehen am 19.05.2022"],"name":{"displayForm":["R. Hehlmann"]},"language":["eng"]} | ||
| SRT | |a HEHLMANNRUTRIALOFIFN3120 | ||